NLRP3 and metabolic dysfunction-associated steatohepatitis: Targeting NLRP3 is a logical direction in pharmacotherapy of NASH and inhibiting its activation has been recently shown to be beneficial against inflammation and fibrosis in experimental NASH in mice [38].